WHY WE STUDY BRAIN CANCER
The most common and aggressive form of adult brain cancer termed glioblastoma (GBM) kills approximately 1200 people per year in Australia. GBM survival is very poor with a median survival of approximately 15 months. Unfortunately, meaningful increases in patient treatment and survival have not changed for decades. New and better therapies to treat these aggressive diseases are urgently needed.
Our laboratory also studies a number of paediatric brain cancers including medulloblastoma and a highly incurable but rare form of brain stem glioma termed diffuse intrinsic pontine glioma (DIPG). Our focus is to define receptors that are only present on children’s brain tumours and not on normal brain. Our goal is to design therapies to target these tumour-specific receptors enabling us to specifically target the tumour while keeping normal healthy developing brain intact.
- Professor Bryan Day, Team Head and Sid Faithfull Fellow
- Professor Andrew Boyd, Honorary Scientist
- Dr Carolin Offenhauser, Postdoctoral Scientist
- Dr Seçkin Akgül, Postdoctoral Scientist
- Dr Rochelle D’Souza, Postdoctoral Scientist
- Fiona Smith, Research Assistant
- Manasi Jiwrajka, MPhil Student
- Michelle Li, PhD Student
- Courtney Jurd, Administration Officer
- Soonjung Lee, Honours Student
- Zara Bruce, Research Assistant
- Kathleen Enesby, Research Assistant
- Yi Chieh Lim, Postdoctoral Scientist
For more information, please view our
Sid Faithfull Brain Cancer Laboratory Information Booklet.
Prof Day’s Selected Key Publications
- Akgül S, Patch AM, D’Souza RCJ, Mukhopadhyay P, Nones K, Kempe S, Kazakoss SH, Jeffree RL, Stringer BW, Pearson JV, Waddell N, Day BW. Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma. Cancers. Jan 2019; 11, 190. IF 5.326.
- Offenhäuser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce, ZC, Jamieson PR, Smith FM, Stringer BW, Carrington B, Fuchs, AV, Bell CA, Jefree R, Rose S, Thurecht KJ, Bowd AW and Day BW. EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. Cancers. Dec 2018; 10 (12), 519. IF 5.326
- Lim YC, Quek H, Offenhäuser C, Lavin M, Boyd AW, Roberts T and Day BW. ATM Inhibition Prevents Interleukin-6 from Contributing to the Proliferation of Glioma Initiating Cells after Ionizing Radiation. Journal of Neuro-Oncology. Jan 2018; 138 (3), 509-518. IF 2.98
- Day BW, Stringer BW and Boyd AW. Eph Receptors as Therapeutic Targets in Glioblastoma. British Journal of Cancer. Invited Review 2014 Sep 23;111 (7):1255-61. IF 5.082
- Day BW, Stringer BW, Wilson J, et al. Glioma Surgical Aspirate: A Viable Source of Tumor Tissue for Experimental Research. Cancers, 5(2), 357-371; April 4, 2013 doi:10.3390/cancers5020357
- Day BW, Stringer BW, Al-Ejeh F, et al. EphA3 Maintains Tumourigenicity and is a Therapeutic Target in Glioblastoma Multiforme. Cancer Cell 23, 238–248, February 11, 2013. IF 26.566
- Day BW, Stringer BW, Spanevello MD, et al. ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1. Neuro Oncology. 2011 Nov;13(11):1202-12. IF 6.2
- Understanding the molecular mechanisms which drive brain cancer recurrence and defining novel therapies to target these aggressive tumour cell
If you wish to apply for QIMR Berghofer's student program,
click here for more information.